Jiong Wu, MD, PhD, is a distinguished professor at Fudan University and vice president of the Fudan University Shanghai Cancer Center
Jiong Wu, MD, PhD, discusses phase 3 PANKU-Breast02 findings showing that izalontamab brengitecan improved progression-free and overall survival vs chemotherapy in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer.
Jiong Wu, MD, PhD, discusses the significance of studying iza-bren in a phase 3 setting in unresectable, locally advanced or metastatic TNBC.
